Adagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference

Key Terms

ventricular tachycardia medical

A fast, abnormal heartbeat that starts in the heart’s lower chambers and can sharply reduce blood flow, potentially causing dizziness, fainting or, in severe cases, sudden collapse; picture an engine running so fast it loses power. For investors, ventricular tachycardia matters because demand for drugs, devices, diagnostic tests and emergency care tied to this condition affects clinical trial results, regulatory approvals, revenue prospects and legal or safety risks for healthcare companies.

ultra-low temperature ablation medical

Ultra-low temperature ablation is a medical technique that destroys unwanted tissue—such as tumors or problematic nerve cells—by freezing them to very low temperatures. Think of it like using a precision freezer to create controlled damage that causes the targeted tissue to die and be removed by the body. Investors care because it represents a specific therapeutic approach with implications for device sales, regulatory approval, clinical adoption, and potential reimbursement, which all affect market opportunity and revenue.

cryoablation medical

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

cardiomyopathy medical

A condition that weakens or stiffens the heart muscle, reducing its ability to pump blood effectively; think of the heart as an engine that becomes less powerful or less flexible. For investors, cardiomyopathy matters because it can drive demand for medical treatments, affect healthcare costs, influence the value of companies developing drugs or devices, and trigger regulatory or insurance impacts that change revenues and risks across the healthcare sector.

nonischemic cardiomyopathy medical

A disease of the heart muscle that weakens its ability to pump blood, caused by factors other than blocked coronary arteries—such as genetics, infections, toxins, or long-term high blood pressure; think of the heart as an appliance that is worn out or damaged by causes other than a clogged pipe. It matters to investors because changes in how common it is, new treatments, trial results, or shifts in long-term care costs can affect insurers, hospitals, drug and device makers, and overall workforce productivity, which in turn can influence related stocks and valuations.

ischemic cardiomyopathy medical

Ischemic cardiomyopathy is a condition in which the heart’s main pumping muscle becomes weak because it hasn’t received enough blood over time, usually due to blockages in the arteries that feed the heart. For investors, it matters because it drives demand for treatments, devices and long‑term care, and it influences healthcare costs and the revenue prospects of companies developing drugs, surgeries, implants or diagnostic tools for heart disease—think of the heart as a pump clogged by narrowed fuel lines.

late-breaking clinical trial medical

A late-breaking clinical trial is newly released, high-impact study data that is shared quickly—often at a medical conference or in a press release—because the results are considered urgent or surprising. For investors, these announcements can change a drug’s outlook overnight, like a sudden weather report that shifts travel plans: they may affect a company’s valuation, regulatory pathway, and near-term stock movement.

pivotal trial medical

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Use of ULTA Across Broad Spectrum of Ventricular Tachycardias to be Highlighted in Multiple Scientific Presentations, Including Late-Breaking Clinical Trial Session

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra-low Temperature Ablation technologies (ULTA) for the treatment of scar-related ventricular tachycardia will be featured in several presentations at the Heart Rhythm Society's 47th Annual Scientific Sessions – Heart Rhythm 2026 conference, to be held from Thursday, April 23 to Sunday, April 26, 2026, in Chicago, Illinois at the McCormick Place Convention Center.

In addition to its booth and technology suite, Adagio’s ULTA technologies will be featured in several events and presentations:

Friday, April 24, 2026

• Ultra-Low Temperature Cryoablation for Inaccessible Ventricular Tachycardia in Right Ventricular Cardiomyopathy: First Reported Cases Using a Novel System, Presented by Dr. Druv Sharma, Vanderbilt University, 11:40–11:50 a.m., Heart Rhythm Hub 5

• Ultra-Low Ventricular Ablation Beyond Clinical Trials: Procedure and MRI Insights from Real-World Patient Series, Presented by Dr. Borislav Dinov, Justus Liebig University Giessen, Germany, 1:00 p.m. at Adagio Booth #1222

• Ultra-Low Temperature Cryoablation of Periaortic Ventricular Tachycardia in Nonischemic Cardiomyopathy: Acute Outcomes from FULCRUM-VT Trial (FP-53573), Presented by Dr. Travis Richardson, Vanderbilt University, 3:15–5:15 p.m., Abstracts Pavilion

• After Hours Case-Based Panel Discussion: Challenges, Hurdles and New Technology Opportunities in Ventricular Ablation, Moderator: Dr. William Stevenson, Vanderbilt University; Panelists: Dr. Atul Verma; Dr. Roderick Tung; Dr. Gregory Supple; Dr. Jeffrey Winterfield; Dr. Mark Gallagher; Dr. Borislav Dinov, 5:30–7:00 p.m. at Adagio Booth #1222

Saturday, April 25, 2026

• Acceleration of Ultra-Low Temperature Ventricular Ablation with Next-Generation Technology: Insights from Pre-Clinical Studies, Presenter: Dr. Katia Dyrda, Montreal Heart Institute, 10:00 a.m., Adagio Booth #1222

• VT Ablation Using Ultralow Cryoablation (AB-532086), Presenter: Dr. Travis Richardson, Vanderbilt University, 11:00–11:12 a.m., Hub 1

• Ultra-Low Temperature Cryoablation of Ventricular Tachycardia due to Ischemic and Nonischemic Cardiomyopathy: Acute Outcomes of FULCRUM-VT Trial (PO-535640), Presenter: Dr. Travis Richardson, Vanderbilt University, 12:00–2:00 p.m., Abstracts Pavilion

• Acute and Mid-term Efficacy of Ultralow Temperature Cryotherapy for Ablation of Ventricular Ectopics (PO-536440), Presenter: Dr. Jaspal Singh Gill, St. George’s Hospital, 12:00–2:00 p.m., Abstracts Pavilion

• Imaging-Guided Scar Assessment Determines Duration of Ultra-Low Temperature Cryoablation for VT Procedures: FULCRUM-VT Substudy (PO-536440), Presenter: Dr. Bishnu Dhakal, Medical University of South Carolina, 12:00–2:00 p.m., Abstracts Pavilion

• Emerging Role of Ultra-Low Temperature Ablation in Management of Periaortic and Right Ventricular VTs (Case-Based Review), Presenters: Dr. William Stevenson and Dr. Hari Tandri, Vanderbilt University, 1:25 p.m. Adagio Booth #1222

• Ultra-Low Ventricular Ablation Beyond Clinical Trials: Procedure and MRI Insights from Real-World Patient Series, Presenter: Dr. Borislav Dinov, 2:55 p.m. Adagio Booth #1222

• Ultra-Low Temperature Ventricular Ablation in Complex Cases – After or Before Everything Else Fails? (Case-Based Review), Presenter: Dr. Gregory Supple, University of Pennsylvania, 4:15 p.m. Adagio Booth #1222

Sunday, April 26, 2026: Late-Breaking Clinical Trial Presentation

• Effectiveness and Safety of Ultra-Low Temperature Ablation of Ventricular Tachycardia in Patients with Structural Heart Disease: Outcomes of the Pivotal FULCRUM-VT Trial, Presenter: Dr. Atul Verma, McGill University Health Centre; Co-Principal Investigator, 8:30 a.m., Room S100c

About Adagio Medical Holdings, Inc.

Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA, formerly known as ULTC) technology. ULTA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue, all through an endocardial approach. The Company is currently focused on the treatment of ventricular arrhythmias with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. Pivotal IDE Trial.

About FULCRUM VT

FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm trial, which has fully enrolled 209 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for U.S. Food and Drug Administration (FDA) premarket approval (PMA) for Adagio’s vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT.

Adagio’s vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic VT in Europe and select other geographies but is limited to investigational use in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416240050/en/

Debbie Kaster
Chief Financial Officer and Chief Business Officer
dkaster@adagiomedical.com

Source: Adagio Medical Holdings, Inc.